Date: November 6th, 2012 | Time: 2pm ET / 11am PT | Duration: 1 hour
Industry leaders and advocates have proposed various alternatives to AWP, but the only consensus to date has been on the criteria that a new drug price benchmark should meet.
Two new drug price types, with quite different approaches, have emerged as possibilities in recent months. National Average Drug Acquisition Cost (NADAC), based on a voluntary CMS survey, and Predictive Acquisition Cost (PAC), which combines a predictive analytics model with multiple factors associated with the cost of a drug.
Attend this webinar to learn more about these drug price types, how they can be used, and which would be more advantageous to payers as a benchmark.
How PAC and NADAC are derived and how they measure against the industry criteria for a new drug pricing benchmark
Which drug price type better supports measuring contract performance, guiding reimbursement rates, and improving negotiating positions
Independent tests, detailed examples and comparisons with AWP for tracking true drug acquisition cost
Business case studies and applications
Dr. Anu Pathria, Pathria Analytics, brings the scientific rigor of predictive analytics to create solutions that tackle the most complex decision-management challenges. Employing advanced statistical modeling techniques to extract meaningful and actionable insights from data.
Todd Grover, ChainDrugStore.net, brings the perspective of manufacturers, wholesalers and payers who need to analyze, understand and manage their pharmacy activity to achieve increased profitability and business efficiencies.